A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF) Combination Compared with FP and FF Monotherapy in Patients with COPD

Trial Profile

A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF) Combination Compared with FP and FF Monotherapy in Patients with COPD

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mylan
  • Most Recent Events

    • 15 Aug 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 24 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top